Description:

In April 2018, after a rigorous preregistered clinical trial that was published in the journal Nature Digital Medicine, the U.S. Food and Drug Administration (FDA) de novo authorized IDx-DR® the first autonomous AI system.  IDx-DR diagnoses (DR) and macular edema in adults who have diabetes and identifies those who need to be referred to eye care.   Two years later in November 2020, EyeArt® was 510k cleared by the FDA to market a similar device.  Based on claims data across all insured, only 15.3% of diabetic patients are receiving annual eye exams.  To tackle this gap in care, healthcare providers are implementing point-of-care tests utilizing autonomous AI technology to complete these diabetic retinal exams outside traditional eyecare settings.  This continuing education will not only reveal how AI technology is changing the way DR and macular edema are identified, but it will also help optometrists prepare for this rapidly evolving healthcare delivery model.

Course Code:

AOA223-PB

Speaker(s):

Dana Weitzman, O.D.
dena.weitzman@gmail.com

Credits:

1

AOA Expiration Date:

3/3/2025

Related News

What optometry’s advocates are championing at AOA on Capitol Hill

Learn about the priority federal issues that hundreds of optometrists and optometry students will take to Capitol Hill as part of optometry’s single-largest annual advocacy gathering, April 14-16, and how you can join.

Representation matters in optometry

Although about 13% of the U.S. population is Black, they are woefully underrepresented in optometry. They represent about 2% of practicing doctors of optometry and a little over 3% of full-time students in optometry schools and colleges, according to studies. Black doctors of optometry seek to grow those numbers.

Making blurry vision clear

February is Low Vision Awareness Month. Take note of considerations for enhancing success with near magnification.